tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Palvella Therapeutics Holds Annual Stockholders Meeting
PremiumCompany AnnouncementsPalvella Therapeutics Holds Annual Stockholders Meeting
1M ago
Palvella Therapeutics receives initial proceeds from FDA Orphan Products grant
Premium
The Fly
Palvella Therapeutics receives initial proceeds from FDA Orphan Products grant
2M ago
Palvella Therapeutics Advances in Rare Skin Disease Therapies
Premium
Company Announcements
Palvella Therapeutics Advances in Rare Skin Disease Therapies
2M ago
Palvella Therapeutics price target raised to $53 from $39 at Canaccord
PremiumThe FlyPalvella Therapeutics price target raised to $53 from $39 at Canaccord
4M ago
Palvella Therapeutics: Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating
Premium
Ratings
Palvella Therapeutics: Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating
4M ago
High-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment
Premium
Ratings
High-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100